Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action
LSI To Be Demerged, Founder Cos Merged In Restructuring
Executive Summary
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.
You may also be interested in...
Alembic Q2 Gets Sartans Shot
Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.
Jubilant Considers Splitting Itself Into Two for Greater Focus
Jubilant’s board is considering whether to create separate entities for its Pharmaceuticals and Life Science Ingredients business segments to give each greater focus.
The Quality Lowdown: Valsartan Options, Supply Chain Warnings, Button Cameras
Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.